FDA Panel Says Pfizer's New Osteoporosis Drug Has Benefits But Use Should Be Restrict

[News]

A panel that advises the US Food and Drug Administration (FDA) on new drug approvals said the benefits of Pfizer's bone drug Fablyn for treating postmenopausal women with osteoporosis outweighed the risks but that use should be restricted to patients at high risk of fracture or who have tried other treatments without success.

More... (http://www.medicalnewstoday.com/articles/120777.php)